TapewireFind a company

person · Reporting owner

Kihara James

Disclosed activity across 1 company

Tapewire entity
34940
SEC CIK
0001816160

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ACADIA PHARMACEUTICALS INCACAD · Entity 3913PRINCIPAL ACCOUNTING OFFICERJune 26, 2026June 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACADIA PHARMACEUTICALS INC

Report date June 26, 2026 · Filed June 29, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect13,088 Reported balance After 2026-06-26 transaction · row 1
1 source row

Row 1 · 2026-06-26 · Sale · Disposed 11,421 · Balance 13,088

F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 9, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 to $26.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Filing footnotes · ownership attribution and instrument terms

F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 9, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 to $26.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 05, 2024 Filed Apr 9, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,010 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-010602 · form4-04092024_060403.xml · derivative · entry 5

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,020

Underlying: Common Stock · 2,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2024 Filed Apr 9, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,010 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-010602 · form4-04092024_060403.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,401

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 25, 2024 Filed Mar 28, 2024 00:02 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 8,568 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-009273 · form4-03282024_120355.xml · derivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,568

Underlying: Common Stock · 8,568 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

Read SEC document
March 25, 2024 Filed Mar 28, 2024 00:02 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 13,964 $0.00 Strike: $17.84 $0.00
Disclosure

SEC source: 0001415889-24-009273 · form4-03282024_120355.xml · derivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,964

Underlying: Common Stock · 13,964 shares

Expires 2034-03-24

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
February 26, 2024 Filed Feb 27, 2024 23:07 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 474 $24.67 $11,693.58
Disclosure

SEC source: 0001415889-24-005574 · form4-02272024_110201.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,391

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
February 23, 2024 Filed Feb 27, 2024 23:07 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 840 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-005574 · form4-02272024_110201.xml · derivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 840

Underlying: Common Stock · 840 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

Read SEC document
February 23, 2024 Filed Feb 27, 2024 23:07 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 840 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-005574 · form4-02272024_110201.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
December 15, 2023 Filed Dec 16, 2023 00:37 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 2,000 $28.30 $56,600.00
Disclosure

SEC source: 0001209191-23-058891 · doc4.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,025

F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

Read SEC document
November 20, 2023 Filed Nov 21, 2023 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,985 $22.64 $44,940.40
Disclosure

SEC source: 0001209191-23-056354 · doc4.xml · nonDerivative · entry 3

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,025

F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.615 to $22.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,982 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-056354 · doc4.xml · derivative · entry 5

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,931

Underlying: Common Stock · 1,982 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

F6 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,982 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-056354 · doc4.xml · derivative · entry 4

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,931

Underlying: Common Stock · 1,982 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,982 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-056354 · doc4.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,010

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,982 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-056354 · doc4.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,028

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 268 shares of the Issuer's common stock acquired by the reporting person on November 15, 2023 pursuant to an employee stock purchase program.

Read SEC document
September 15, 2023 Filed Sep 19, 2023 22:31 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 2,000 $25.88 $51,760.00
Disclosure

SEC source: 0001209191-23-050072 · doc4.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,778

F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

F2 · balance_after: Includes an aggregate of 3,611 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on November 13, 2020, May 14, 2021, November 15, 2021, May 13, 2022, November 15, 2022 and May 15, 2023.

F3 · balance_after: Includes 23 shares purchased by the Reporting Person in open market transaction on November 21, 2020, with a purchase price of $43.01 per share.

Read SEC document
June 15, 2023 Filed Jun 16, 2023 20:38 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 2,000 $24.15 $48,300.00
Disclosure

SEC source: 0001209191-23-037932 · doc4.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,144

F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.

Read SEC document
May 17, 2023 Filed May 19, 2023 22:54 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 5,947 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-031245 · doc4.xml · derivative · entry 5

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,913

Underlying: Common Stock · 5,947 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

F4 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Read SEC document
May 17, 2023 Filed May 19, 2023 22:54 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 5,947 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-031245 · doc4.xml · derivative · entry 4

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,913

Underlying: Common Stock · 5,947 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F3 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
May 17, 2023 Filed May 19, 2023 22:54 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 5,947 $22.50 $133,807.50
Disclosure

SEC source: 0001209191-23-031245 · doc4.xml · nonDerivative · entry 3

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,144

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
May 17, 2023 Filed May 19, 2023 22:54 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 5,947 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-031245 · doc4.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,091

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
May 17, 2023 Filed May 19, 2023 22:54 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 5,947 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-031245 · doc4.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,144

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
May 01, 2023 Filed May 4, 2023 01:13 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 10,384 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-027203 · doc4.xml · derivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,384

Underlying: Common Stock · 10,384 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Read SEC document
May 01, 2023 Filed May 4, 2023 01:13 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 17,131 $0.00 Strike: $21.75 $0.00
Disclosure

SEC source: 0001209191-23-027203 · doc4.xml · derivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,131

Underlying: Common Stock · 17,131 shares

Expires 2033-05-01

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
April 10, 2023 Filed Apr 12, 2023 01:15 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 523 $18.14 $9,487.22
Disclosure

SEC source: 0001209191-23-024061 · doc4.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,197

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.14 to $18.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
April 07, 2023 Filed Apr 12, 2023 01:15 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,489 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-024061 · doc4.xml · derivative · entry 3

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,489

Underlying: Common Stock · 1,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024.

F4 · derivative.expiration_date: 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024.

Read SEC document
April 07, 2023 Filed Apr 12, 2023 01:15 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,489 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-024061 · doc4.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
April 06, 2023 Filed Apr 8, 2023 00:41 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 701 $18.16 $12,730.16
Disclosure

SEC source: 0001209191-23-023864 · doc4.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,231

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
April 05, 2023 Filed Apr 8, 2023 00:41 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,009 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-023864 · doc4.xml · derivative · entry 3

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,030

Underlying: Common Stock · 2,009 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2023 Filed Apr 8, 2023 00:41 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,009 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-023864 · doc4.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,932

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
February 24, 2023 Filed Feb 28, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 350 $18.78 $6,573.00
Disclosure

SEC source: 0001209191-23-013471 · doc4.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,923

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
February 23, 2023 Filed Feb 28, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 840 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-013471 · doc4.xml · derivative · entry 3

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,680

Underlying: Common Stock · 840 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

Read SEC document
February 23, 2023 Filed Feb 28, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 840 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-013471 · doc4.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,273

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
April 08, 2022 Filed Apr 12, 2022 00:02 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,025 $27.05 $27,726.25
Disclosure

SEC source: 0001209191-22-024064 · doc4.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,433

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
April 07, 2022 Filed Apr 12, 2022 00:02 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,977 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-024064 · doc4.xml · derivative · entry 3

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,978

Underlying: Common Stock · 2,977 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024.

F3 · derivative.expiration_date: 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024.

Read SEC document
April 07, 2022 Filed Apr 12, 2022 00:02 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,977 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-024064 · doc4.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,458

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

Read SEC document
April 05, 2022 Filed Apr 7, 2022 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 8,039 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-023743 · doc4.xml · derivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,039

Underlying: Common Stock · 8,039 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2022 Filed Apr 7, 2022 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 13,793 $0.00 Strike: $25.75 $0.00
Disclosure

SEC source: 0001209191-22-023743 · doc4.xml · derivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,793

Underlying: Common Stock · 13,793 shares

Expires 2032-04-05

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 22:45 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 840 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-013286 · doc4.xml · derivative · entry 3

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,520

Underlying: Common Stock · 840 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 22:45 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 359 $23.80 $8,544.20
Disclosure

SEC source: 0001209191-22-013286 · doc4.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 481

F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 22:45 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 840 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-013286 · doc4.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 840

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 17, 2021 Filed Nov 19, 2021 23:36 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 15,860 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-065928 · doc4.xml · derivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,860

Underlying: Common Stock · 15,860 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

F3 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Read SEC document
November 17, 2021 Filed Nov 19, 2021 23:36 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 15,860 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-065928 · doc4.xml · derivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,860

Underlying: Common Stock · 15,860 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F2 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F2 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
February 23, 2021 Filed Feb 26, 2021 02:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 3,360 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-014560 · doc4.xml · derivative · entry 2

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,360

Underlying: Common Stock · 3,360 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022.

Read SEC document
February 23, 2021 Filed Feb 26, 2021 02:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 6,187 $0.00 Strike: $49.74 $0.00
Disclosure

SEC source: 0001209191-21-014560 · doc4.xml · derivative · entry 1

Kihara James · CIK 0001816160 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,187

Underlying: Common Stock · 6,187 shares

Expires 2031-02-23

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2022. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.